Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 17/20 | 1.00 |
| ▸ | PPARG | P37231 | 10/20 | 1.00 |
| ▸ | PPARD | Q03181 | 7/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5074798 | 0.88 | PPARA (1.00) | PPARAPPARGPPARD | |
| SCHEMBL4426257 | 0.87 | PPARA (1.00) | PPARAPPARGPPARD | |
| SCHEMBL5141089 | 0.87 | PPARA (1.00) | PPARAPPARGPPARD | |
| SCHEMBL4429948 | 0.87 | PPARA (1.00) | PPARAPPARGPPARD | |
| SCHEMBL4429876 | 0.87 | PPARD (1.00) | PPARAPPARGPPARD | |
| SCHEMBL18644320 | 0.87 | PPARD (1.00) | PPARAPPARGPPARD | |
| SCHEMBL5074799 | 0.87 | PPARA (0.77) | PPARAPPARGPPARD | |
| SCHEMBL4782627 | 0.85 | PPARA (1.00) | PPARAPPARGPPARD | |
| SCHEMBL4424394 | 0.85 | PPARA (1.00) | PPARAPPARGPPARD | |
| SCHEMBL4426872 | 0.84 | PPARA (1.00) | PPARAPPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7524882-B2 | PPAR alpha selective compounds for the treatment of dyslipidemia and other lipid disorders | MERCK & CO., INC. (US) | 2009-04-28 | — | — | US | claimed |
| EP-1539136-B1 | PPAR ALPHA SELECTIVE COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER LIPID DISORDERS | MERCK & CO INC (US) | 2008-07-09 | — | — | EP | claimed |
| EP-1539136-A4 | PPAR ALPHA SELECTIVE COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER LIPID DISORDERS | MERCK & CO INC (US) | 2006-10-18 | — | — | EP | claimed |
| US-20050228044-A1 | Ppar alpha selective compounds for the treatment of dyslipidemia and other lipid disorders | MERCK SHARP & DOHME CORP. | 2005-10-13 | — | — | US | claimed |
| EP-1539136-A2 | PPAR ALPHA SELECTIVE COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER LIPID DISORDERS | Merck & Co., Inc. (US) | 2005-06-15 | — | — | EP | claimed |
| WO-2004010936-A2 | PPAR ALPHA SELECTIVE COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER LIPID DISORDERS | MERCK & CO., INC. (US) | 2004-02-05 | — | — | WO | claimed |
| US-7524882-B2 | PPAR alpha selective compounds for the treatment of dyslipidemia and other lipid disorders | MERCK & CO., INC. (US) | 2009-04-28 | — | — | US | disclosed |
| US-7524882-B2 | PPAR alpha selective compounds for the treatment of dyslipidemia and other lipid disorders | MERCK & CO., INC. (US) | 2009-04-28 | — | — | US | disclosed |
| US-7524882-B2 | PPAR alpha selective compounds for the treatment of dyslipidemia and other lipid disorders | MERCK & CO., INC. (US) | 2009-04-28 | — | — | US | disclosed |
| EP-1539136-B1 | PPAR ALPHA SELECTIVE COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER LIPID DISORDERS | MERCK & CO INC (US) | 2008-07-09 | — | — | EP | disclosed |
| EP-1539136-A4 | PPAR ALPHA SELECTIVE COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER LIPID DISORDERS | MERCK & CO INC (US) | 2006-10-18 | — | — | EP | disclosed |
| US-20050228044-A1 | Ppar alpha selective compounds for the treatment of dyslipidemia and other lipid disorders | MERCK SHARP & DOHME CORP. | 2005-10-13 | — | — | US | disclosed |
| EP-1539136-A2 | PPAR ALPHA SELECTIVE COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER LIPID DISORDERS | Merck & Co., Inc. (US) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004010936-A2 | PPAR ALPHA SELECTIVE COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER LIPID DISORDERS | MERCK & CO., INC. (US) | 2004-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050228044-A1 | Ppar alpha selective compounds for the treatment of dyslipidemia and other lipid disorders | PPARD, PPARA, PPARG | PPARA 2/4885PPARG 3/4885PPARD 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.